Status:

UNKNOWN

Ganglion Plexus Ablation in Persistent Atrial Fibrillation

Lead Sponsor:

Ning Zhou

Conditions:

Atrial Fibrillation, Persistent

Ganglionated Plexi

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

This study aims to investigate the long-term efficacy and safety of incorporating ganglionated plexus ablation into radiofrequency ablation strategies for persistent atrial fibrillation.

Detailed Description

1. Study Design: The study employs a parallel-group design with a 1:1 randomization ratio. Eligible patients meeting the specified criteria will be randomly assigned to either the conventional abl...

Eligibility Criteria

Inclusion

  • Age between 18 and 80 years, regardless of gender.
  • Patients confirmed by electrocardiogram or clinically diagnosed with persistent atrial fibrillation.
  • Individuals scheduled to undergo atrial fibrillation catheter ablation.
  • Willing to participate in the study and voluntarily sign the informed consent form.

Exclusion

  • Patients with a history of prior atrial fibrillation ablation surgery.
  • Left ventricular ejection fraction (LVEF) less than 35%.
  • Left atrial anterior-posterior diameter greater than 50mm on echocardiography.
  • Presence of contraindications for atrial fibrillation ablation, such as the presence of clear thrombus in the left atrium detected preoperatively.
  • Patients with second-degree (Type II) or third-degree atrioventricular block.
  • Individuals with significant congenital heart defects (such as atrial septal defects or severe pulmonary vein stenosis, excluding unclosed foramen ovale).
  • Patients with implanted artificial valves.
  • Diagnosed with hypertrophic cardiomyopathy, chronic obstructive pulmonary disease, or myxoma.
  • Untreated or uncontrolled hyperthyroidism or hypothyroidism.
  • Patients with active systemic infections.
  • Individuals with a significant bleeding tendency or those undergoing active blood dialysis due to renal failure.
  • Patients who have experienced myocardial infarction within the last 3 months or undergone any cardiac intervention/open-heart surgery.
  • Presence of clear contraindications for interventional procedures, as determined by the investigator.
  • Pregnant or lactating women, or those planning pregnancy during the study period.
  • Participation in other drug or medical device clinical trials within the last 3 months.
  • Patients deemed unsuitable for participation in this clinical trial by the investigator.

Key Trial Info

Start Date :

January 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2024

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT06181578

Start Date

January 1 2024

End Date

December 31 2024

Last Update

December 26 2023

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.